Capital Increase / Dilution2026-06-26

LigaChem Biosciences Decides on Paid-in Capital Increase

LCB

리가켐바이오

141080

+0.05

Signal Score

52CNeutral
Score52 / 100

Historical Avg Return (5d)

+0.31%

Data Coverage

100%n=2386

Risk-adjusted indicator based on 2386 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Board Resolution Date: June 25, 2026
  • • Conversion Price: 149,300 KRW per share
  • • Conversion Price Calculation Basis (Highest of C and D): 149,220 KRW
  • • 1-month Weighted Average Stock Price (A): 142,195.70 KRW
  • • 1-week Weighted Average Stock Price (B): 141,508.81 KRW
  • • Latest Day Weighted Average Stock Price (C): 149,220.00 KRW

AI Analysis Summary

LigaChem Biosciences Inc. announced a decision on a paid-in capital increase via convertible preferred shares, with the board resolution dated June 25, 2026. The conversion price is set at 149,300 KRW per share, based on a 3.46% premium over the calculated reference stock price. The preferred shares carry voting rights identical to common shares and include a call option for the issuer from 24 to 48 months post-issuance, allowing the company to repurchase up to 10% of the shares at a price reflecting a 1% annual compound interest. The specific number of shares and total funding amount are not yet disclosed, pending confirmation of third-party allocators. The shares will be subject to a one-year lock-up period and will not be listed until converted to common shares. The purpose of the capital increase and the specific allocators will be disclosed in a subsequent amendment.

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.